Literature DB >> 7680054

Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin.

K Toriyama1, D R Wen, E Paul, A J Cochran.   

Abstract

We examined the frequency, distribution, and immunophenotype (S-100 protein, CD1) of epidermal Langerhans cells (LC) in the epidermis overlying primary melanoma, and dermal dendritic cells (DC) in the dermis deep to melanoma, and in adjacent normal skin. There is a substantial reduction in S-100+ LC and a lesser decline in CD1+ LC in the epidermis over melanoma. There is a simultaneous increase in the frequency of cells expressing these phenotypes in the dermis deep to tumor. Double-staining studies in progress show coexpression of S-100 and CD1 in most of these cells. The depletion of S-100+/CD1+ DC from the peritumoral epidermis is maximum in deeper (Clark level III-V) and thicker (> 0.76 mm) tumors. The reduction in total DC in peritumoral epidermis is, however, proportionally less than the reduction in S-100+/CD1+ DC owing to an increase in cells that are S-100-/CD1+. The proportion of S-100+/CD1+ dermal DC deep to tumor is similar to that in normal epidermis and dermis, suggesting that there is no increased migration of S-100-/CD1+ DC from tumor-associated epidermis to subjacent dermis. Non-dendritic leukocytes in the dermis deep to tumor were increased in frequency, maximally in the dermis deep to thinner and more superficial melanomas. Most such cells were T lymphocytes with helper/inducer cells predominating. The data presented show substantial alterations in the frequency, distribution, and phenotype of LC/DC as melanoma evolves, alterations that may be critical for development of effective tumor-directed immunity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680054     DOI: 10.1111/1523-1747.ep12470135

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  16 in total

1.  Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells.

Authors:  Barbara G Molenkamp; Ronald J C L M Vuylsteke; Paul A M van Leeuwen; Sybren Meijer; Wim Vos; Pepijn G J T B Wijnands; Rik J Scheper; Tanja D de Gruijl
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

2.  Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

Authors:  Pawel Kalinski; Howard Edington; Herbert J Zeh; Hideho Okada; Lisa H Butterfield; John M Kirkwood; David L Bartlett
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

3.  Langerhans cells and melanocytes share similar morphologic features under in vivo reflectance confocal microscopy: a challenge for melanoma diagnosis.

Authors:  Pantea Hashemi; Melissa P Pulitzer; Alon Scope; Ivanka Kovalyshyn; Allan C Halpern; Ashfaq A Marghoob
Journal:  J Am Acad Dermatol       Date:  2011-07-28       Impact factor: 11.527

Review 4.  Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.

Authors:  Pawel Kalinski; Hideho Okada
Journal:  Semin Immunol       Date:  2010-04-20       Impact factor: 11.130

Review 5.  Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4.

Authors:  Pawel Kalinski
Journal:  Curr Opin Investig Drugs       Date:  2009-06

Review 6.  Dendritic cell-based therapeutic cancer vaccines: what we have and what we need.

Authors:  Pawel Kalinski; Julie Urban; Rahul Narang; Erik Berk; Ewa Wieckowski; Ravikumar Muthuswamy
Journal:  Future Oncol       Date:  2009-04       Impact factor: 3.404

Review 7.  The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.

Authors:  Peter E Fecci; Duane A Mitchell; Gary E Archer; Michael A Morse; H Kim Lyerly; Darell D Bigner; John H Sampson
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

8.  Human melanoma cells inhibit the earliest differentiation steps of human Langerhans cell precursors but failed to affect the functional maturation of epidermal Langerhans cells.

Authors:  O Berthier-Vergnes; M Gaucherand; J Péguet-Navarro; J Plouet; J F Pageaux; D Schmitt; M J Staquet
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

9.  Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins.

Authors:  G Pirtskhalaishvili; G V Shurin; C Esche; Q Cai; R R Salup; S N Bykovskaia; M T Lotze; M R Shurin
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

10.  Dendritic cells in the cancer microenvironment.

Authors:  Yang Ma; Galina V Shurin; Zhu Peiyuan; Michael R Shurin
Journal:  J Cancer       Date:  2012-12-15       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.